Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France

BMC Health Services Research

Volumn 11, Issue , 2011, Pages

  Cotté, François Emery ^a,b   De Pouvourville, Gérard ^c  

^a INSERM   (France)

^b GLAXOSMITHKLINE   (France)

^c ESSEC BUSINESS SCHOOL   (France)

Author keywords

adherence; bisphosphonate; cost; modelling study; osteoporosis; persistence

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; COST; ECONOMICS; FEMALE; FRACTURE; FRANCE; HUMAN; MIDDLE AGED; MONTE CARLO METHOD; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE OSTEOPOROSIS;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COSTS AND COST ANALYSIS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; FRANCE; HUMANS; MIDDLE AGED; MONTE CARLO METHOD; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 79959406146     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-11-151     Document Type: Article

References (53)

1. Study Group Report: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization, World Health Organ Tech Rep Ser 1994 843 1 129 7941614
2. Indicateurs de suivi de l'atteinte des 100 objectifs du rapport annexé la loi du 9 aot 2004 relative la politique de santé publique [in French]. Ministry of Health and Solidarity (Ministère de la Santé et des Solidarités), La documentation française 2005 http://www.ladocumentationfrancaise.fr/rapports/index.shtml
3. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. UA Liberman SR Weiss J Broll HW Minne H Quan NH Bell J Rodriguez-Portales RW Downs Jr J Dequeker M Favus, N Engl J Med 1995 333 22 1437 43 10.1056/NEJM199511303332201 7477143
4. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud, Lancet 1996 348 1535 41 10.1016/S0140-6736(96)07088-2 8950879 (Pubitemid 26411651)
5. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. PJ Meunier PD Delmas R Eastell MR McClung S Papapoulos R Rizzoli E Seeman RD Wasnich, Clin Ther 1999 21 6 1025 44 10.1016/S0149-2918(99)80022-8 10440625 (Pubitemid 29326161)
6. An integrated approach: bisphosphonate management for the treatment of osteoporosis. G Owens R Jackson EM Lewiecki, Am J Manag Care 2007 13 S11 290 308 18095779
7. Characterisation of patients with postmenopausal osteoporosis in French primary healthcare. F Blotman B Cortet P Hilliquin B Avouac FA Allaert D Pouchain AF Gaudin FE Cotté A El Hasnaoui, Drugs Aging 2007 24 7 603 14 10.2165/00002512-200724070-00007 17658910 (Pubitemid 47195678)
8. Analysis of pharmacy and hospital drug sales in France: data of 1998-2008. French Health Products Safety Agency (AFSSAPS), 10 2010 http://www.afssaps.fr
9. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. JA Kanis CC Glüer, Osteoporos Int 2000 11 192 202 10.1007/s001980050281 10824234 (Pubitemid 30216170)
10. Prevalence and features of osteoporosis in the French general population: the Instant study. E Lespessailles FE Cotté C Roux P Fardellone F Mercier AF Gaudin, JBS 2009 76 4 394 400
11. Compliance and persistence with osteoporosis therapies. SL Silverman DT Gold, Curr Rheumatol Rep 2008 10 2 118 22 10.1007/s11926-008-0021-x 18460266
12. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. JA Cramer NO Lynch AF Gaudin M Walker W Cowell, Clin Ther 2006 28 10 1686 94 10.1016/j.clinthera.2006.10.013 17157124 (Pubitemid 44838898)
13. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization E Sabaté WHO Report 2003
14. Adherence to treatment of osteoporosis: a need for study. F Lekkerkerker JA Kanis G Bouvenot N Burlet D Cahall A Chines P Delmas RL Dreiser D Ethgen N Hughes JM Kaufman S Korte G Kreutz A Laslop B Mitlak V Rabenda R Rizzoli A Santora R Schimmer Y Tsouderos P Viethel JY Reginster Group for the Respect of Ethics and Excellence in Science (GREES), Osteoporos Int 2007 18 10 1311 17 10.1007/s00198-007-0410-4 17585359 (Pubitemid 47389473)
15. Medication compliance and persistence: terminology and definitions. JA Cramer A Roy A Burrell CJ Fairchild MJ Fuldeore DA Ollendorf PK Wong, Value Health 2008 11 44 47 10.1111/j.1524-4733.2007.00213.x 18237359 (Pubitemid 351160875)
16. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. DA Hughes A Bagust A Haycox T Walley, Health Econ 2001 10 7 601 15 10.1002/hec.609 11747044 (Pubitemid 32998372)
17. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. International Society for Pharmacoeconomics & Outcomes Research Economics of Medication Compliance Working Group. D Hughes W Cowell T Koncz J Cramer International Society for Pharmacoeconomics & Outcomes Research Economics of Medication Compliance Working Group, Value Health 2007 10 6 498 509 10.1111/j.1524-4733.2007.00205.x 17970932
18. A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis. FE Cotté B Fautrel G De Pouvourville, Med Decis Making 2009 29 1 125 39 10.1177/0272989X08318461 18566486
19. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. DT Gold BC Martin JR Frytak MM Amonkar F Cosman, Curr Med Res Opin 2007 23 3 585 94 10.1185/030079906X167615 17355739 (Pubitemid 46456906)
20. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. CH van den Boogaard NS Breekveldt-Postma SE Borggreve WG Goettsch RM Herings, Curr Med Res Opin 2006 22 9 1757 64 10.1185/030079906X132370 16968579 (Pubitemid 44449232)
21. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis. FE Cotté F Mercier G De Pouvourville, Clin Ther 2008 30 12 2410 2422 10.1016/j.clinthera.2008.12.019 19167600
22. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. JJ Caro KJ Ishak KF Huybrechts G Raggio C Naujoks, Osteoporos Int 2004 15 12 1003 8 10.1007/s00198-004-1652-z 15167989 (Pubitemid 40064656)
23. Epidemiology and outcomes of osteoporotic fractures. SR Cummings LJ Melton, Lancet 2002 359 9319 1761 7 10.1016/S0140-6736(02)08657-9 12049882
24. A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France. FE Cotté B Cortet A Lafuma B Avouac AE Hasnaoui P Fardellone D Pouchain C Roux AF Gaudin, JBS 2008 75 2 201 8 (Pubitemid 351418261)
25. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. CM Klotzbuecher PD Ross PB Landsman TA Abbott M Berger, J Bone Miner Res 2000 15 721 39 10780864 (Pubitemid 30174026)
26. Treatment of established osteoporosis: a systematic review and cost-utility analysis. JA Kanis JE Brazier M Stevenson NW Calvert M Lloyd Jones, Health Technol Assess 2002 6 1 146 10.1007/978-94-010-0481-7-1 12925269
27. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. YZ Bagger LB Tanko P Alexandersen P Ravn C Christiansen, Bone 2003 33 301 7 10.1016/S8756-3282(03) 00112-1 13678770 (Pubitemid 37103246)
28. Comparaison of the persistance of daily and weekly bisphosphonates in French female patients treated for osteoporosis. P Fardellone AF Gaudin FE Cotté A Lafuma C Marchand A El Hasnaoui, J Bone Miner Re 2005 20 S1 1 S512 SU416
29. Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). AA Ismail TW O'Neill C Cooper JD Finn AK Bhalla JB Cannata P Delmas JA Falch B Felsch K Hoszowski O Johnell JB Diaz-Lopez A Lopez Vaz F Marchand H Raspe DM Reid C Todd K Weber A Woolf J Reeve AJ Silman, Osteoporos Int 1998 8 291 7 10.1007/s001980050067 9797915 (Pubitemid 28427080)
30. Mortality after low-energy fractures in patients aged at least 45 years old. NL Shortt CM Robinson, J Orthop Trauma 2005 19 6 396 400 10.1097/01.bot.0000155311.04886.7e 16003199
31. Nomenclature des actes médicaux. Base des Médicaments et Informations Tarifaires [in French]. National Health Insurance (Assurance Maladie), http://www.ameli.fr
32. Arrêté du 4 mai 2006 modifiant la liste des spécialités pharmaceutiques remboursables aux assurés sociaux [in French]. Official Journal of the French Republic (Journal Officiel de la République Française), http://www.legifrance.gouv.fr
33. 2009 PMSI Database [in French]. Technical Agency for Hospital Information (Agence Technique de l'Information Hospitalière), http://www.atih.sante. fr
34. 2008 Database [in French]. National Cost Study (Etude Nationale des Cots) for Disease Related Groups, http://www.atih.sante.fr
35. Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries. S Bouée A Lafuma F Fagnani PJ Meunier JY Reginster, Rheumatol Int 2006 26 12 1063 72 10.1007/s00296-006-0180-x 16953395 (Pubitemid 44450839)
36. Case finding for the management of osteoporosis with FRAX - assessment and intervention thresholds for the UK. JA Kanis EV McCloskey H Johansson O Strom F Borgstrom A Oden National Osteoporosis Guideline Group, Osteoporos Int 2008 19 10 1395 408 10.1007/s00198-008-0712-1 18751937
37. Drug insight: Bisphosphonates for postmenopausal osteoporosis. RD Chapurlat PD Delmas, Nat Clin Pract Endocrinol Metab 2006 2 4 211 9 10.1038/ncpendmet0121 16932286
38. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. S Epstein M Jeglitsch E McCloskey, Curr Med Res Opin 2009 25 12 2951 60 10.1185/ 03007990903361307 19835464
39. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. FE Cotté P Fardellone F Mercier AF Gaudin C Roux, Osteoporos Int 2010 21 1 145 55 10.1007/s00198-009-0930-1 19459025
40. Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women. V Breuil B Cortet FE Cotté B Arnould C Dias-Barbosa AF Gaudin A Regnault A Roborel de Climens E Legrand, Osteoporos Int 2011
41. Patient preferences for oral versus intravenous palliative chemotherapy. G Liu E Franssen MI Fitch E Warner, J Clin Oncol 1997 15 1 110 5 8996131 (Pubitemid 27021524)
42. Non-compliance with medication regimens and subsequent hospitalization: A literature analysis and cost of hospitalization estimate. SD Sullivan DH Kreling TK Hazlet, J Res Pharm Econ 1990 2 19 33
43. Noncompliance: a $100 billion problem. A Lewis, Remington Report 1997 5 14 5
44. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. MR DiMatteo, Med Care 2004 42 3 200 9 10.1097/01.mlr.0000114908.90348.f9 15076819
45. Prevalence and cost of medication nonadherence in Parkinson's disease: Evidence from administrative claims data. KL Davis HM Edin JK Allen, Mov Disord 2010 25 4 474 80 10.1002/mds.22999 20131374
46. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. KL Davis SD Candrilli HM Edin, Epilepsia 2008 49 3 446 54 10.1111/j.1528-1167.2007.01414.x 18031549 (Pubitemid 351294534)
47. The economic implications of non-adherence after renal transplantation. I Cleemput K Kesteloot Y Vanrenterghem S De Geest, Pharmacoeconomics 2004 22 18 1217 34 10.2165/00019053-200422180-00006 15606228 (Pubitemid 40075723)
48. Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus. J Munakata JS Benner S Becker CM Dezii EH Hazard JC Tierce, Med Care 2006 44 10 893 9 10.1097/01.mlr.0000233679.20898.e9 17001259 (Pubitemid 44454565)
49. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. SB Cherry JS Benner MA Hussein SS Tang MB Nichol, Value Health 2009 12 4 489 97 10.1111/j.1524-4733. 2008.00447.x 18783393
50. A pharmacoeconomic analysis of compliance gains on antipsychotic medications. J Damen PO Thuresson B Heeg M Lothgren, Appl Health Econ Health Policy 2008 6 4 189 97 19382819
51. Evaluation of the efficacy and cost effectiveness of health education methods to increase medication adherence among adults with asthma. RA Windsor WC Bailey JM Richards B Manzella SJ Soong M Brooks, Am J Public Health 1990 80 12 1519 21 10.2105/AJPH.80.12.1519 2240348
52. Patient education and compliance: how to make it cost-effective? JM McKenney, Value Health 1998 1 4 212 5 10.1046/j.1524-4733.1998.140212.x 16674541 (Pubitemid 128499441)
53. French Guidelines for the Economic Evaluation of Health Care Technologies. French Health Economists Association (Collège des Economistes de la Santé), 2004 http://www.ces-asso.org